Free Trial

Nevro Q1 2023 Earnings Report

Nevro logo
$5.84 +0.05 (+0.86%)
As of 03:58 PM Eastern

Nevro EPS Results

Actual EPS
-$0.98
Consensus EPS
-$1.06
Beat/Miss
Beat by +$0.08
One Year Ago EPS
-$0.98

Nevro Revenue Results

Actual Revenue
$96.33 million
Expected Revenue
$95.35 million
Beat/Miss
Beat by +$980.00 thousand
YoY Revenue Growth
+9.70%

Nevro Announcement Details

Quarter
Q1 2023
Time
After Market Closes

Conference Call Resources

Remove Ads

Nevro Earnings Headlines

Nevro (NYSE:NVRO) Coverage Initiated at StockNews.com
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
Nevro is not issuing FY25 guidance
See More Nevro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nevro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nevro and other key companies, straight to your email.

About Nevro

Nevro (NYSE:NVRO), a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

View Nevro Profile

More Earnings Resources from MarketBeat